Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

In detail (June 19) -

Brean Capital analyst Difei Yang reiterated a Buy rating and boosted its price target on Momenta Pharmaceuticals (NASDAQ: MNTA) to $31.00 (from $25.00) on high likilihood of Glatopa being the only generic Copaxone on market for extended period of time.

"Due to an earlier-than-expected launch (June vs. our estimation of September, 2015) coupled with the expected favorable competitive market condition, i.e., less price discount, more market share, we are significantly revising our EPS estimates up," Yang commented. "As a result, our price target increases from $25 to $31."

http://www.streetinsider.com/Analyst+Comments/Momenta+Pharmaceuticals+(MNTA)+PT+Raised+to+$31+at+Brean+Capital/10665045.html